Table 1 Baseline characteristics of patients with SAA treated with or without MSCs

Median age, years (range)

4 (1-10)

5 (3-9)

0.438

Gender, male / female

3 / 6

5 / 4

0.637

 SAA, n (%)

2 (22%)

4 (44%)

0.620

 vSAA, n (%)

7 (78%)

5 (56%)

Median duration from diagnosis to ATG treatment, days (range)

26 (9-159)

39 (26-179)

0.281

Median WBC, ×10⁹/L (range)

1.84 (0.57-4.79)

2.60 (0.65-5.23)

0.699

Median HGB, g/L (range)

76 (47-117)

65 (47-105)

0.475

Median PLT,×10⁹/L (range)

10 (1-18)

8 (4-19)

0.500

Median ANC,×10⁹/L (range)

0.07 (0-0.36)

0.13 (0.01-0.41)

0.229

Median ARC,×10⁹/L (range)

5.4 (2.6-32.8)

4.5 (2.2-17.0)

0.587

Median percentage of CD3 + CD4+ T-cell lymphocytes, % (range)

39.6 (35.7-42.9)

43.2 (28.4-73.0)

0.401

Median percentage of CD3 + CD8+ T-cell lymphocytes, % (range)

25.6 (14.1-35.1)

25.8 (9.4-35.2)

0.885

Median percentage of Tregs, % (range)^a

7.0 (3.5-9.4)

6.7 (2.2-16.8)

0.763

Median percentage of mature lymphocytes in BM, % (range)

94.1 (44.5-98.5)

87.9 (36.2-97.7)

0.306